Use of colchicine to inhibit tumor growth and metastases
AssigneeMurray and Poole Enterprises Ltd
InventorMichael Riel
Life of this patent
Estimating the term…
Abstract
Use of colchicine to inhibit tumor growth and metastases in mammalian subjects comprising the administration of the compositions and formulations are provided. The described colchicine compositions and formulations include sustained release, and multimodal release compositions and formulations suitable for alone or in combination with additional pharmaceutically active agents useful in treating tumor growth and metastases.
Claims22
A method for inhibiting, delaying, or reducing tumor growth or metastases or both tumor growth and metastases in a subject diagnosed with or suffering from cancer, comprising administering to the subject a sustained release formulation comprising:
- (a) granules comprising between 0.1 mg to 0.60 mg of colchicine or a pharmaceutically acceptable salt thereof;
- (b) a binder, wherein the binder is hydroxypropyl methylcellulose (HPMC) 6 mPa·s in an amount of 1% to 30% (w/w) of the formulation;
- (c) a retarding agent in an amount of 5% to 40% (w/w) of the formulation, wherein the retarding agent is a spray agglomerated blend of equal parts by weight of HPMC with a viscosity grade of 4000 mPa·s and lactose monohydrate;
- and
- (d) at least one pharmaceutically acceptable excipient blended with the granules,
- wherein the sustained release formulation is a tablet.
A method for inhibiting, delaying, or reducing tumor growth or metastases or both tumor growth and metastases in a subject diagnosed with or suffering from cancer, comprising administering to the subject a sustained release formulation comprising:
- (a) granules comprising between 0.1 mg to 0.60 mg of colchicine or a pharmaceutically acceptable salt thereof;
- (b) a binder, wherein the binder is hydroxypropyl methylcellulose (HPMC) 6 mPa·s in an amount of 1% to 30% (w/w) of the formulation;
- (c) a retarding agent in an amount of 5% to 40% (w/w) of the formulation, wherein the retarding agent is a spray agglomerated blend of equal parts by weight of HPMC with a viscosity grade of 4000 mPa·s and lactose monohydrate;
- and
- (d) at least one pharmaceutically acceptable excipient blended with the granules,
- wherein the sustained release formulation is a tablet,
- and an effective amount of at least one other immune modulating agent or immune modulating therapy.
Dependencies are inferred from the claim text.